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Androgen deprivation therapy (ADT) remains a mainstay in the treatment of prostate cancer 
(PCa) since the discovery 70 years ago by Charles Huggins that castration results in regression of 
prostate cancer (PCa)
1
.  ADT can be achieved either surgically (orchiectomy) or pharmacologi-
cally with gonadotropin-releasing hormone (GnRH) analogues.  Alternatively, some patients 
wishing to maintain sexual potency may elect for treatment with anti-androgens (AA), recogniz-
ing that outcomes are inferior to ADT in the metastatic setting
2
.  
GnRH agonists (GnRHa) have largely replaced orchiectomy due to their ease of administration, 
reversibility, the avoidance of disfiguring surgery, and likely (at least in part) to the financial in-
centive afforded to prescribing physicians
3
.  With an established role in the treatment of high 
risk, locally advanced, and metastatic disease, ADT is frequently prescribed to patients suffering 
from prostate cancer.  However, ADT is not free of risk:  In addition to the well known side ef-
fects of fatigue, hot flushes, decreased libido and sexual potency, gynecomastia, and reduced pe-
nile and testicular size, prospective studies have shown decreased bone mineral density, weight 
gain, decreased insulin sensitivity, and increases in fasting glucose, LDL cholesterol, and triglyc-
erides
4
.  Of even greater concern is that a number of observational studies have found an in-
creased risk of fractures, diabetes mellitus (DM), peripheral arterial disease (PAD), venous 
thromboembolism (VTE), and cardiovascular disease (CVD)
4-6
.  While this has not been sup-
ported by data from randomized controlled trials, these data prompted the FDA to mandate 
changes to GnRHa labelling to include a warning of the increased risk of DM and CVD.  
 
In the article that accompanies this editorial
7
, Sun et al report interesting findings. Using the Sur-
veillance, Epidemiology and End Results (SEER) program of cancer registries matched to Medi-
 4 
care data, the authors investigated the risk of fracture, PAD, VTE, cardiac-related complications, 
DM and cognitive disorders in patients with metastatic PCa treated with GhRHa,  or bilateral or-
chiectomy between 1995 and 2009 and compared the expenditures within the first 12 months af-
ter diagnosis of PCa. In adjusted analyses, they report that patients who were treated with bilat-
eral orchiectomy had a lower risk of fractures (HR 0.77), PAD (HR 0.65), and cardiac-related 
complication (HR 0.74) compared to patients receiving GnRHa. However, no statistical differ-
ences were noted between the treatments in term of risk of DM and cognitive disorders, except 
patients receiving ≥35 months of GnRHa had a higher risk of DM compared to patients undergo-
ing orchiectomy. Moreover, they report no significant difference in expenditures between the 
two groups 12 months after Pca diagnosis. 
 
Sun and colleagues should be lauded for their contribution to this subject.  Most publications ad-
dressing the adverse effects of ADT have involved either exclusively or predominately non-
metastatic PCa patients, and therefore have been written with the undercurrent of “do no harm”.   
However for patients with metastatic PCa, ADT remains essential and therefore the question be-
comes: Can we do less harm? Prior studies have suggested a lower risk of adverse events with 
orchiectomy compared to GnRHa, however definitive conclusions could not be drawn because of 
the lack of a direct comparison
6,8
. The current study has used the GnRHa group as the reference 
to which the orchiectomy group is compared, allowing for a critically important direct compari-
son between the two forms of ADT.  Focusing on these patients results in a smaller, but more 
homogenous group than other observational studies.  Importantly, patients who received AA as 
well as those with a baseline condition were excluded from this study to reduce the risk of bias.  
Use of AA could represent a confounding variable as they may influence the risk of CV events.  
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While this study has many strengths, one must be conscious of its limitations.  Attempts were 
made to account for the differences between the groups analyzed, but there may be other key 
variables unaccounted for despite the propensity analysis.  These include the use of bone anti-
resorptive agents, corticosteroids, and diethyilstilboestrol, which are are commonly used in the 
treatment of metastatic PCa and impact the risk of fractures, diabetes and VTE.  Furthermore, 
patients treated with GnRHa were stratified based on time on treatment, yet the same stratifica-
tion was not pursued for the other groups. This may be relevant since some endpoints such as of 
fractures, CVD, and cognitive decline are associated with advancing age.  Caution must also be 
exercised when interpreting studies of cognitive function, as it is difficult to measure even under 
ideal circumstances.  Relying on diagnostic codes in a Medicare database has limited utility in 
detecting the frequently subtle symptoms that patients experience. Surprisingly, the effect of 
ADT on cognitive function is not well established; the largest randomized controlled trial ad-
dressing the subject showed no consistent adverse effect after 12 months of ADT in prostate can-
cer patients, compared to both prostate cancer patients not receiving ADT and healthy controls
9
.  
And while the expenditures analysis is an important addition, the 12-month time window evalu-
ated likely does not provide an accurate assessment of the cost differences associated with the 
two forms of ADT:  patients undergoing orchiectomy are faced with the up-front cost of a surgi-
cal procedure, while patients who chose GnRHa face continuing drug and administration costs.  
Furthermore, if patients who receive GnRHa have higher rates of complications, the medical 
costs of those will increase over time.   
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That orchiectomy may be associated with a lower risk of CVD compared to GnRHa is not alto-
gether surprising, although controversial.  Some studies have found that GnRHa, but not orchiec-
tomy, are associated with excess CVD risk compared to non-ADT treated controls
6,8
; while a re-
cent meta-analysis of observational studies has found an increased risk of CVD with both 
GnRHa and orchiectomy
10
.  Nevertheless, the lower risk of fracture is unexpected as a large ob-
servational study found orchiectomy to be associated with a similar if not higher risk of fracture 
compared to GnRHa
11
. Overall, it remains possible that no true difference exists between or-
chiectomy and GnRH agonists. Indeed, the number of patients undergoing orchiectomy in this 
study is relatively small and observational study bias due to unmeasured differences between the 
treatment groups is a significant risk.  For this reason prospective trials are warranted. 
 
If a true difference between these forms of ADT exists, GnRHa may play a direct role in the 
pathogenesis of these adverse events.    GnRH receptors are present on many extra-pituitary tis-
sues, including the heart, with some evidence that GnRHa directly mediate cardiac contractility 
and intracellular calcium concentration
12
.  GnRH receptors are also present on T-lymphocytes, 
with agonists possibly promoting inflammation and contributing to the destabilization of athero-
sclerotic plaques, increasing the risk of plaque rupture and thrombotic events
13
. Studies in mice 
have shown that the GnRHa leuprolide causes atherosclerotic plaque instability, while the GnRH 
antagonist degarelix does not
14
.  Interestingly, a meta-analysis of trials comparing degarelix to 
GnRH agonists showed a lower incidence of cardiac events within 1 year of initiating treatment 
in men with pre-existing CV disease
15
.  
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Despite their retrospective nature, studies such as this are critically important, as they increase 
awareness of these concerns.  As men with metastatic PCa are living longer than ever, it is im-
perative that we minimize the risk of harm from therapies. Physicians treating PCa patients must 
familiarize themselves with how to prevent and manage these complications (see Nguyen 2015 
for a review of the subject
4
). The current article by Sun adds fuel to an already controversial de-
bate, and the discredit brought by the reimbursement issues.  When there is more than one rea-
sonable option, clinical decisions must be guided by the patient’s values and preferences.    In the 
absence of clear evidence to the contrary, patients are likely to continue to overwhelmingly fa-
vour GnRHa over orchiectomy. 
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